Adrenocortical carcinoma market seen reaching $4.62 billion by 2030

The market for adrenocortical carcinoma treatments is projected to grow from $3.76 billion in 2025 to $4.62 billion by 2030 as rare-cancer diagnosis, targeted therapies and combination regimens expand. North America leads the market now, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Adrenocortical carcinoma is a rare, aggressive cancer, so even modest growth in diagnosis and treatment demand can have an outsized effect on specialized care, research funding and access to expertise. - Rising rare-cancer detection is expanding the patient pool that health systems and drug developers need to serve. - The market outlook points to continued investment in diagnostic tools, surgical approaches and drug development for a disease with limited treatment options.

What happened: - The Business Research Company projected the global adrenocortical carcinoma market will rise from $3.76 billion in 2025 to $3.92 billion in 2026. - The report said the market is expected to reach $4.62 billion by 2030, implying a 4.2% CAGR from 2026 to 2030. - The report was published as a 2026 global market analysis focused on demand patterns and the competitive landscape. - The company released a free sample and a full report for readers seeking more detail: Download the sample report and View the full report.

The details: - Adrenocortical carcinoma originates in the adrenal cortex, the outer part of the adrenal glands above each kidney. - The disease can disrupt hormone production tied to metabolism, immune response, blood pressure and stress. - Reported symptoms include unexplained weight gain, hypertension and virilization, which is the development of male physical characteristics. - The report linked recent growth to limited awareness of ACC symptoms, dependence on traditional surgery, low disease prevalence, scarce specialized treatment centers and better diagnostic imaging. - Future growth is tied to targeted therapies, broader use of minimally invasive and laparoscopic methods, more specialized cancer research institutes, stronger patient education and wider use of combination therapy regimens. - Rare cancers are defined by the International Agency for Research on Cancer as fewer than 6 new cases per 100,000 people annually. - Rare cancers account for about 25% of all cancer diagnoses globally, according to the February 2024 IARC report.

Between the lines: - The market is growing because ACC is difficult to detect early and hard to treat at scale, which pushes demand toward more precise diagnostics and specialist-led care. - North America’s lead reflects stronger infrastructure, research capacity and patient awareness. - Asia-Pacific’s expected growth suggests more demand will come from improving access to diagnostics and treatment, not just from higher disease recognition. - The report’s emphasis on TAM analysis, company scoring, forecasting dashboards and trend graphics signals that buyers want competitive intelligence, not just market sizing.

What's next: - The report expects the market to keep growing through 2030 as early detection improves and more advanced therapies gain adoption. - North America should remain the largest regional market in the near term. - Asia-Pacific is positioned to be the fastest-growing region as healthcare investment and medical infrastructure expand. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The bottom line: - ACC remains a small but growing oncology market, and the next phase of expansion is likely to come from better detection, more specialized care and more treatment options.